688202.SHG Shanghai Medicilon Inc
- Market cap
- CNY 10.5B
- P/E
- -
- P/B
- 4.56x
- ROE
- 6.0%
- Dividend yield
- 0.07%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 688202.SHG undervalued?
Graham numberThe Graham number of Shanghai Medicilon Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Shanghai Medicilon Inc fundamental analysis
No fundamental analysis for Shanghai Medicilon Inc yet.
Shanghai Medicilon Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Shanghai Medicilon Inc
Shanghai Medicilon Inc., a contract research organization, provides drug discovery and development services to pharmaceutical and biotechnology companies in China and internationally. The company operates in Drug Discovery and Pharmaceutical Research, and Preclinical Research segments. It offers drug discovery, CMC development, preclinical research, biology, chemistry, catalyst screening, flow chemistry, carbohydrate chemistry, analytical chemical, ADME/DMPK, pharmacology, s…
Full company profileShanghai Medicilon Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Shanghai Medicilon Inc annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 232M | 249M | 325M | 449M | 666M | 1.17B | 1.66B | 1.37B | 1.04B | 1.16B | 1.62B |
| Gross Profit | 84.1M | 85.5M | 119M | 161M | 274M | 529M | 677M | 325M | 65.5M | 202M | 498M |
| Operating Income | 46.7M | 48.7M | 67.6M | 75.6M | 149M | 331M | 382M | 6.14M | -216M | -97.7M | 186M |
| EBITDA | - | 61.0M | 79.4M | 91.6M | 171M | 383M | 452M | 54.2M | -261M | -65.0M | 135M |
| Net Income | 43.4M | 41.6M | 60.8M | 66.6M | 129M | 282M | 338M | -33.2M | -331M | -168M | 123M |
| EPS | - | 0.90 | 1.31 | 1.07 | 2.09 | 4.55 | 3.89 | -0.25 | -2.46 | -1.25 | 0.91 |
| Balance Sheet | |||||||||||
| Total Assets | 345M | 390M | 473M | 1.13B | 1.36B | 1.79B | 2.33B | 3.27B | 2.82B | 2.62B | 2.90B |
| Total Liabilities | 98.8M | 102M | 125M | 128M | 229M | 466M | 727M | 755M | 683M | 688M | 851M |
| Shareholders' Equity | 243M | 283M | 342M | 993M | 1.12B | 1.33B | 1.60B | 2.51B | 2.14B | 1.93B | 2.05B |
| Cash & Short-term Investments | 144M | 157M | 167M | 636M | 466M | 412M | 197M | 472M | 261M | 287M | 273M |
| Cash Flow | |||||||||||
| Operating Cash Flow | 34.1M | 74.7M | 71.1M | 58.3M | 208M | 453M | -21.3M | 33.3M | -22.7M | 105M | - |
| Capital Expenditure | 39.3M | 58.9M | 64.4M | 97.4M | 119M | 293M | 404M | 300M | 110M | 69.0M | 205M |
| Free Cash Flow | - | 15.8M | 6.73M | -39.1M | 89.0M | 160M | -425M | -283M | -133M | 36.1M | 151K |
| Ratios | |||||||||||
| ROE | 17.8% | 14.7% | 17.7% | 6.7% | 11.5% | 21.3% | 21.1% | -1.3% | -15.5% | -8.7% | 6.0% |
| ROA | 12.6% | 10.7% | 12.8% | 5.9% | 9.5% | 15.7% | 14.5% | -1.0% | -11.7% | -6.4% | 4.2% |
| Net Profit Margin | 18.7% | 16.7% | 18.7% | 14.8% | 19.4% | 24.2% | 20.4% | -2.4% | -31.9% | -14.4% | 7.6% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Shanghai Medicilon Inc dividends
- Dividend yield
- 0.07%
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- Jun 2, 2023
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 7.42M | 0.06 | - |
| 2024 | CNY 6.97M | 0.05 | - |
| 2023 | CNY 41.0M | 0.30 | - |
| 2022 | CNY 87.3M | 1.00 | 25.8% |
| 2021 | CNY 39.1M | 0.63 | 13.8% |
| 2020 | CNY 39.1M | 0.63 | 30.2% |
| 2019 | CNY 39.1M | 0.63 | 58.7% |
| 2018 | CNY 39.1M | 0.84 | 64.3% |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.4:1 on Jun 2, 2023.
Who owns Shanghai Medicilon Inc
- Insiders 39.66%
- Institutions 16.46%
- Public & others 43.88%
- Shares outstanding 134M
- Free float 79.1M
Shanghai Medicilon Inc company profile
- Company name
- Shanghai Medicilon Inc
- Ticker
- 688202.SHG
- ISIN
- CNE100003NQ8
- Exchange
- Shanghai Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 2,504
- Fiscal year end
- December
- Address
- No. 585, Chuanda Road, Shanghai, China, 201299
- Phone
- 86 21 5859 1500
- Website
- medicilon.com.cn
About Shanghai Medicilon Inc
Shanghai Medicilon Inc., a contract research organization, provides drug discovery and development services to pharmaceutical and biotechnology companies in China and internationally. The company operates in Drug Discovery and Pharmaceutical Research, and Preclinical Research segments. It offers drug discovery, CMC development, preclinical research, biology, chemistry, catalyst screening, flow chemistry, carbohydrate chemistry, analytical chemical, ADME/DMPK, pharmacology, safety assessment, IND-Enabling studies, and advanced technology services. The company also provides peptide, SiRNA, ADC, Protac, AOCs, NAMs Platforms. The company was founded in 2004 and is based in Shanghai, China.
Shanghai Medicilon Inc management
10- Dr. Chun-Lin Chen Ph.D.Co-Founder, Chairman & CEO · born 1962
- Mr. Shuangqing Peng Ph.D.Chief Scientific Officer · born 1962
- Dr. Jinna Cai Ph.D.Chief Commercial Officer, Deputy GM & Director · born 1964
- Ms. Binbin LiuDeputy General Manager · born 1977
- Mr. Jianglin HuJoint CEO, Executive VP & Chief Strategy and Development Officer · born 1970
- Ms. Donghua ZhangFinancial Director · born 1985
- Fang Hong ChenAccounting Supervisor
- Dr. Lilly Xu Ph.D.Chief Technology Officer
- Ms. Jiang Xu MBAManager of Human Resources Department
- Dr. Haizhou ZhangPresident of Preclinical R&D Unit